Article Text

Download PDFPDF
▼Quinupristin + dalfopristin for infections
  • Relevant BNF section: 5.1.7


&#9660Quinupristin + dalfopristin* (Synercid-Aventis Pharma Ltd) is a new combination antibacterial product licensed for treating patients with a variety of Gram-positive infections. Here we assess its place in clinical practice.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

  • Relevant BNF section: 5.1.7

View Full Text